病毒性结膜炎治疗市场按药物类别、病毒类型、通路和地区划分

病毒性结膜炎治疗市场规模预计在 2025 年为 3.75 亿美元，预计到 2032 年将达到 5.312 亿美元，2025 年至 2032 年的复合年增长率为 5.1%。

病毒性结膜炎是由多种病毒引起的急性结膜感染疾病，包括腺病毒和单纯疱疹病毒。病毒性结膜炎占感染性结膜炎的大多数，占病例的 75%。病毒性结膜炎的特征包括眼红、血管充血、眼分泌物、疼痛和畏光。由腺病毒组引起的病毒性结膜炎称为流行性角结膜炎 (EKC)。这组腺病毒具有多种血清型，也可引起咽结膜热和特异性滤泡性结膜炎。根据发表在《美国眼科学会：2018》上的一篇论文，腺病毒性结膜炎是成人族群中最常见的眼部感染疾病。腺病毒性结膜炎传染性极强，因为引起感染的病毒可以在工作檯面和类似表面存活数週。

市场动态

开发人员正在进行临床试验，以开发更有效的腺病毒性结膜炎治疗方法，这很可能在预测期内促进市场成长。例如，2017年，工业的子公司Shire Plc开始进行临床试验，以检验其候选药物SHP640在治疗成人和儿童腺病毒性结膜炎的安全性和有效性。

市场参与企业正专注于推出新产品，预计这些产品将巩固其在全球市场的地位。例如，2018年，艾伯维公司（Abbvie Inc.）的子公司艾尔建公司（Allergan plc.）推出了一款新的非处方（OTC）人工泪液配方「Refresh Repair润滑眼药水」。此配方含有羧甲基纤维素钠（CMC）、透明质酸（HA，非活性成分）和渗透保护剂，可保护眼睛免受结膜发炎症状（例如干眼症）的不利影响。

市场参与企业正积极与其他公司建立伙伴关係关係，加强分销，从而扩大其全球影响力，预计这将推动病毒性结膜炎药物市场的成长。例如，2018年，德国萌蒂製药公司（Mundipharma Deutschland GmbH & Co.KG）与义大利製药公司NTC建立商业合作伙伴关係，获得在拉丁美洲授权和分销一系列眼科药物的独家权利，从而扩大了其在拉丁美洲的眼科药物组合。

研究的主要特点

• 本报告对全球病毒性结膜炎治疗市场进行了详细分析，并以 2024 年为基准年，对 2025 年至 2032 年期间的市场规模进行了预测。
• 它揭示了不同领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球病毒性结膜炎治疗市场的主要企业已根据公司概况、财务绩效、产品系列、地理位置、分销策略、关键发展和策略以及未来计划等参数进行了分析。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、技术改进、市场扩张和行销策略做出明智的决策。
• 全球病毒性结膜炎治疗药物市场报告涉及该行业的各个相关人员，例如投资者、供应商、製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过病毒性结膜炎药物市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 市场机会
• 影响分析
• 最近的测试启动
• 流行病学
• 合併、收购与合作
• 监管情景
• PEST分析

4. 2020 年至 2032 年全球病毒性结膜炎药物市场（依药物类别）

• 介绍
• 抗生素
• 人工泪液
• 鼻减充血剂
• 抗组织胺药
• NSAIDs
• 抗病毒药物
• 其他的

5. 全球病毒性结膜炎药物市场（依病毒类型划分），2020 年至 2032 年

• 介绍
• 腺病毒
• 肠病毒
• 其他（单纯疱疹病毒（HSV）等）

6. 2020-2032 年全球病毒性结膜炎药物市场（依通路）

• 介绍
• 医院药房
• 零售药局
• 网路药局

7. 2020 年至 2032 年全球病毒性结膜炎药物市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 东南亚国协
  • 澳洲
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 北非
  • 中部非洲
  • 南非

第八章 竞争态势

• 公司简介
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.mbH
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

第九章 章节

• 参考
• 调查方法

Viral Conjunctivitis Drugs Market is estimated to be valued at USD 375 Mn in 2025 and is expected to reach USD 531.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study

• This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.

Market Segmentation

• Global Viral Conjunctivitis Drugs Market, By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
• Global Viral Conjunctivitis Drugs Market, By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
• Global Viral Conjunctivitis Drugs Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Viral Conjunctivitis Drugs Market, By Region
  • North America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Middle East
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox
  • NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 -2032, (USD Mn)
  • Segment Trends

5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Viral Conjunctivitis Drugs Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020 -2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2020-2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Nicox, NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Santen Pharmaceutical Co.Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact